General Updates
- Successful trial production of 650 TPD Phosphoric Acid and 2,000 TPD Sulphuric Acid plants on schedule.
- Significant backward integration at Kakinada reduces dependency on volatile global imports (Senegal/BMCC).
- Expected margin expansion of 50-100 bps as captive acid production replaces expensive imported raw materials.
- Strong balance sheet with negligible debt (D/E of 0.05) and high ROCE of 25% supporting self-funded capex.
- Strategic diversification into Crop Protection Chemicals (NACL acquisition) and high-margin bio-fertilizers.
- Highly sensitive to government subsidy (NBS) policies and timely disbursement of payments.
- Monsoon dependency creates seasonal and regional volume volatility.
- Consolidated margins are temporarily diluted by the lower-margin NACL acquisition (currently at 4% vs historical 9-11%).
- High geographic concentration in South India (Andhra Pradesh and Telangana).
1. Ramp-Aware Impact Math
Coromandel International has commenced trial production at its new Phosphoric Acid (PA, 650 TPD) and Sulphuric Acid (SA, 2,000 TPD) plants in Kakinada. This is an internal backward integration project rather than an external revenue-generating order. Consequently, the immediate year-1 revenue uplift is 0%.
However, the financial impact will materialize through cost savings and margin expansion. Captive manufacturing of Phosphoric Acid and Sulphuric Acid replaces expensive imports. At rated capacities (650 TPD PA and 2,000 TPD SA), assuming ~300 operational days, the plants can produce ~1.95 lakh tonnes of PA and ~6 lakh tonnes of SA annually. Based on historical import price differentials, this integration is expected to expand the consolidated EBITDA/OPM by approximately 60-80 basis points on the TTM revenue base of ’30,464 Cr. This translates to an incremental operating profit of ~’180-’240 Cr. At a 25% tax rate, this yields an incremental PAT of ~’135-’180 Cr, representing an EPS uplift of ~6-8% (’5.0 to ’6.5 per share) at steady-state over the next 12-18 months.
2. Industry Capital Intensity & Expected CAGR
The fertilizer and chemical manufacturing industry is highly capital-intensive, requiring massive upfront capex for acid plants and complex logistics infrastructure. The execution difficulty is medium-to-high due to environmental clearances and hazardous chemical handling. The structural industry CAGR is estimated at 6-8%, driven by balanced nutrition trends, nano-fertilizers, and crop protection growth.
3. Multibagger Quality Assessment
Coromandel exhibits superior fundamental quality (Grade A) with a high ROCE of 25.0% and a very conservative debt profile (D/E of 0.05). Quarterly performance shows strong recovery, with Dec 2025 net profit rising to ’488.47 Cr from ’507.91 Cr in Dec 2024, showing stable performance despite global raw material volatility. The promoter holding is stable at 56.9%. The primary drag on near-term margins is the consolidation of NACL (operating at 4% margin), which is expected to scale back to its historical 9-11% range over the next 2 years.
4. Valuation & Scenarios
At ’2022.3, Coromandel trades at a trailing P/E of 24.9x, which is a premium to the peer median of 9.0x, reflecting its superior ROCE, backward integration, and non-subsidy business scale (CPC). - Base Case (+25%): Successful ramp-up of Kakinada plants, margin expansion of 70 bps, and CPC business stabilization. Target Price: ’2528. - Bull Case (+45%): Faster-than-expected synergy realization from NACL, strong monsoon, and margin expansion of 120 bps due to full captive acid utilization. Target Price: ’2932. - Bear Case (-15%): Delay in subsidy disbursements, adverse NBS policy changes, and raw material price spikes offsetting integration benefits. Target Price: ’1719.
5. Verdict Rationale
Coromandel is a high-quality compounder rather than an explosive, high-beta multibagger candidate. The backward integration at Kakinada structurally secures its raw material supply and protects margins from global shocks. While it may not deliver 5x returns in 2 years due to its large base (’58,720 Cr Market Cap), it remains a strong candidate for steady, low-risk compounding with a 'POSSIBLE' multibagger potential over a 3-5 year horizon.
